Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 18, 2014

View Archived Issues

Sosei subsidiary to commence development of two ophthalmic products

Universite de Montreal receives grant from Quebec government for drug development

Regeneron initiates phase I study of intravitreal REGN-2176-3 for wet AMD

Inhibition of protein kinase-induced gene expression is protective against influenza virus infection

Bayer initiates new phase III study of rivaroxaban within EINSTEIN program

GSK researchers present data on novel LSD1 inhibitors

Biomarker-driven development of resminostat

Russian group claims new peptide-based compounds for Abeta accumulation

Galapagos completes recruitment in phase II GLPG-0974 trial

Last patient treated in phase III CicloMulsion study

AXIN2 gene as a potential new biomarker for prostate cancer recurrence

Novartis acquires CoStim Pharmaceuticals

HIV vaccine obtains FDA orphan drug status for pediatric HIV/AIDS infection

Canadian researchers design novel MAbs to human GnRH receptor

Bristol-Myers Squibb divulges novel agents for thromboembolic disorders

FDA grants orphan drug status to rosuvastatin calcium in pediatric HoFH

American and Chinese researchers synthesize novel agents for cancer

Cellectis and Servier enter collaboration to develop allogeneic cell therapies for cancer

Sunshine Biopharma builds mouse models to test Adva-27a in pancreatic cancer

Achelios Therapeutics to begin phase Ib study of topical ELS-M11 for migraine

National Comprehensive Cancer Network recommends Yondelis in trials of uterine leiomyosarcoma

DBV Technologies and Mount Sinai enter collaboration to develop Viaskin for Crohn's disease

Phase III trial of Bayer's long-acting, site-specific recombinant factor VIII meets primary endpoint

Daiichi Sankyo and UMN Pharma form research collaboration to develop norovirus vaccine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...